Search Results

You are looking at 21 - 30 of 1,650 items for :

  • "chemotherapy" x
Clear All
Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff and Gary H. Lyman

. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 3. Hryniuk W Bush H . The importance of dose intensity in chemotherapy of metastatic breast cancer . J Clin Oncol

Full access

Darren R. Feldman, Wendy L. Schaffer and Richard M. Steingart

metastatic disease can be cured with cisplatin-based chemotherapy with or without surgery. Unfortunately, over the past 2 decades, data have emerged linking chemotherapy, particularly cisplatin, with several late toxicities, with cardiovascular disease chief

Full access

Sally Yowell Barbour

.medscape.org/journal/jnccn ; (4) view/print certificate. Release date: April 9, 2012; Expiration date: April 9, 2013. Learning Objectives Upon completion of this activity, participants will be able to: Assess the classification of CINV Distinguish chemotherapy

Full access

Ting Bao

cancer nausea and vomiting . J Clin Oncol 2008 ; 26 : 3903 – 3910 . 2 Hickok JT Roscoe JA Morrow GR . Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of

Full access

Jeremy Lund, Angela Pearson and Georgia Keriazes

Background The American Cancer Society estimates that more than 1.6 million new cancer cases were diagnosed in the United States in 2014. 1 Chemotherapy is often an option for the treatment of cancer either alone or as adjunct to radiation or

Full access

Robert E. Smith Jr.

://www.nccn.org . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy

Full access

Sujana Movva, Margaret von Mehren, Eric A. Ross and Elizabeth Handorf

, chemotherapy can be administered in the adjuvant setting with the goal of decreasing the risk of recurrence and improving OS. These goals must be balanced with the potential long-term toxicity. In 1997, the Sarcoma Meta-Analysis Collaboration (SMAC) performed

Full access

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas and Robert E. Bristow

) view/print certificate. Release date: May 12, 2016; Expiration date: May 12, 2017 Learning Objectives Upon completion of this activity, participants will be able to: Identify risk factors associated with refusal of recommended chemotherapy

Full access

Andrew G. Robinson, Xuejiao Wei, William J. Mackillop, Yingwei Peng and Christopher M. Booth

will present with advanced disease or develop metastatic disease after presentation. 1 For patients with advanced disease, clinical trials suggest that multiagent cisplatin-based chemotherapy is associated with improved survival. Regimens studied

Full access

Gary H. Lyman and Jessica Malone Kleiner

discussed in the article or their competitors. References 1. Dale DC McCarter GC Crawford J . Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials . J Natl Compr Canc Netw 2003 ; 1 : 440